Drug Target Discovery Group
Professor Tutt's group aims to identify and validate new molecular targets and to develop drugs through the process of hit generation, lead identification and candidate selection.
Professor Andrew Tutt
Director of Breast Cancer Now Toby Robins Research Centre & Head of Division:
Drug Target Discovery, Breast Cancer Collaborations, Target Validation & DNA Damage Response
Andrew Tutt is Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR and Guy’s Hospital King’s College London. He is a Clinician Scientist with the Laboratory and Clinical Trials programme, and a Consultant Clinical Oncologist looking after women with breast cancer.
Researchers in this group
.
Professor Andrew Tutt's group have written 171 publications
Most recent new publication 8/2024
See all their publicationsIndustrial partnership opportunities with this group
Opportunity: Cancer biomarker for predicting response to drugs targeting mitotic checkpoint kinases and cell division
Commissioner: Professor Andrew Tutt, Professor Chris Lord, Professor Jonathon Pines
Recent discoveries from this group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
Researchers identify what drives PARP inhibitor resistance in advanced breast cancer
-(3)-4088-x-3076.jpg?sfvrsn=81e087bc_2 "Breast cancer cell Credit Breast cancer cell spheroid,Attribution 4.0 International (CC BY 4.0) (3) 4088 x 3076")
ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer
-547x410.jpg?sfvrsn=5e98f2c_2 "Clinical trials pharmacy (Jan Chlebik for the ICR, 2014) 547x410")